Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin for Prediabetes in HIV Patients
NCT05135039Unknown
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in prediabetes comparing Canagliflozin Arm with Placebo Arm (2 arms). Primary endpoint: Rate of progression from prediabetes to diabetes at 1 year. Status: unknown.
02
Drugs
canagliflozin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT05135039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135039.